Dynavax Technologies (DVAX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Dynavax Technologies is set to report its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.12 per share and revenue of $87.55 million.
• The company previously reported a loss of $0.11 EPS in Q1 2025, which missed analysts' expectations by $0.14.
• Analysts have recently decreased their target prices for DVAX, with JMP Securities lowering it to $31.00, and Goldman Sachs setting a target of $10.00.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $87.55 million for the quarter.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). The company had revenue of $68.16 million for the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. On average, analysts expect Dynavax Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Dynavax Technologies Stock Performance

Shares of DVAX stock traded down $0.11 during trading on Friday, reaching $10.87. 838,800 shares of the company's stock were exchanged, compared to its average volume of 2,112,484. The company has a quick ratio of 10.84, a current ratio of 11.93 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $1.31 billion, a PE ratio of -20.93 and a beta of 1.03. Dynavax Technologies has a twelve month low of $9.22 and a twelve month high of $14.63. The firm's fifty day moving average price is $10.36 and its 200-day moving average price is $11.62.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DVAX. The Goldman Sachs Group decreased their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. Wall Street Zen lowered Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. Finally, JMP Securities reduced their price objective on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies currently has an average rating of "Hold" and an average target price of $24.00.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd bought a new position in shares of Dynavax Technologies during the first quarter worth about $180,000. Caxton Associates LLP bought a new stake in shares of Dynavax Technologies during the first quarter valued at approximately $225,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Dynavax Technologies by 1.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company's stock valued at $1,126,000 after acquiring an additional 1,625 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Dynavax Technologies by 7.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company's stock valued at $5,838,000 after acquiring an additional 29,764 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.